Reviva Pharmaceuticals to Host Key Opinion Leader Webinar on Brilaroxazine for Schizophrenia and Other Neuropsychiatric Disorders
April 26, 2022 06:00 ET
|
Reviva Pharmaceuticals
Virtual event on Tuesday, May 3rd at 10:00 AM ET An overview of unmet medical needs and therapeutic opportunities in schizophrenia and major neuropsychiatric disorders will be discussed CUPERTINO,...
Reviva Pharmaceuticals Holdings, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report®
March 24, 2022 07:30 ET
|
Reviva Pharmaceuticals
CUPERTINO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies...
Reviva Pharmaceuticals Holdings, Inc. to Participate at the Maxim Virtual Growth Conference
March 22, 2022 08:00 ET
|
Reviva Pharmaceuticals
CUPERTINO, Calif., March 22, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies...
Reviva Pharmaceuticals Holdings, Inc. to Present at Upcoming Virtual Investor Conferences
March 18, 2022 08:00 ET
|
Reviva Pharmaceuticals
- 5th Annual Neuroscience Innovation Forum - - BIO-Europe Spring® 2022 - CUPERTINO, Calif., March 18, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the...
Reviva Pharmaceuticals Holdings, Inc. Reports Full Year 2021 Financial Results and Recent Business Highlights
March 15, 2022 17:16 ET
|
Reviva Pharmaceuticals
- Topline data for pivotal Phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia anticipated in mid-2023 - $29.7 Million in Cash as of December 31, 2021 - CUPERTINO, Calif.,...
Reviva Pharmaceuticals Announces First Patients Dosed in Pivotal Phase 3 Study and Long-Term Safety Trial Evaluating Brilaroxazine for the Treatment of Schizophrenia
February 01, 2022 06:00 ET
|
Reviva Pharmaceuticals
- RECOVER is a Phase 3, randomized, double-blind study with registrational intent - - Reviva anticipates expanding the clinical development of brilaroxazine into other neuropsychiatric indications - ...
Reviva Pharmaceuticals Holdings, Inc. Receives FDA May Proceed Letter for Pivotal Phase 3 Clinical Trial and Long-Term Safety Trial Evaluating Brilaroxazine For The Treatment of Schizophrenia
January 10, 2022 06:00 ET
|
Reviva Pharmaceuticals
- Brilaroxazine is a novel serotonin and dopamine receptor modulator currently being developed for diseases with dysfunctional serotonin signaling including neuropsychiatric and pulmonary indications...
Reviva Pharmaceuticals to Participate in the Upcoming January Virtual Investor Conferences
December 20, 2021 07:00 ET
|
Reviva Pharmaceuticals
CUPERTINO, Calif., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies...
Reviva Pharmaceuticals Holdings, Inc. Reports Third Quarter 2021 Financial Results and Recent Business Highlights
November 15, 2021 08:15 ET
|
Reviva Pharmaceuticals
- Initiation of a pivotal Phase 3 trial evaluating the efficacy and safety of brilaroxazine for the treatment of schizophrenia expected by year-end - - Additional Phase 3 trial evaluating the...
Reviva Pharmaceuticals to Present at the Upcoming Benzinga Healthcare Small Cap Conference
September 15, 2021 08:30 ET
|
Reviva Pharmaceuticals
CUPERTINO, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies...